Ann: Notice received under section 249D of the Corporations Act, page-2

ImpediMed Limited (ImpediMed or the Company) (ASX: IPD) advises that in accordance with ASX
Listing Rule 3.17A it has received a notice under section 249D of the Corporations Act 2001 (Cth)
(Corporations Act) from the shareholders listed in the Schedule (Requisitioning Parties) holding at
least 5% of the votes that may be cast at a general meeting of the Company.
The Requisitioning Parties have requested that the directors of the Company call and arrange to hold a
general meeting of the Company for the purposes of considering eight proposed resolutions, of which:
• four resolutions are proposed for the removal of each of Don Williams, Amit Patel, David
Anderson and Daniel Sharp as directors of the Company; and
• four resolutions are proposed for the appointment of each of McGregor Grant, Christine
Emmanuel-Donnelly, Andrew Grant and Janelle Delaney as directors of the Company.
The Company has also received a members’ statement under section 249P of the Corporations Act
which will be circulated to shareholders in accordance with the Company’s requirements under the
Corporations Act. The members’ statement outlines the rationale of the requisition, being a perceived
disconnect between the Australian shareholders and the present board relating to the Company’s recent
capital raising and perceived risks to shareholder wealth. The company will respond to the statement in
due course.
The Company is considering the notices and will keep shareholders updated on any material
developments, including the timing of the general meeting. The general meeting will be held no later
than 2 October 2023, being two months after the section 249D request was given to the Company.
If shareholders have any questions on this matter, they are welcome to direct their queries to the
Managing Director and Chief Executive Officer, Rick Valencia.